NCT04074135View on ClinicalTrials.gov

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

PHASE2RecruitingINTERVENTIONAL
Enrollment

740

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

January 30, 2036

Study Completion Date

July 1, 2036

Conditions
VHL Pancreatic Neuroendocrine TumorsVon Hippel-Lindau DiseaseNeuroendocrine Tumors
Interventions
DRUG

68-Gallium DOTATATE

68-Gallium DOTATATE, to be used in yearly PET/CT research scans

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH